Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-06-21
2011-06-21
Duffy, Patricia A (Department: 1645)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S023700, C435S320100, C424S184100
Reexamination Certificate
active
07964576
ABSTRACT:
The present invention provides methods of selecting and uses of anti-arthropod vector vaccines to prevent Leishmaniasis. The present invention also provides compositions for vaccines to prevent Leishmaniasis.
REFERENCES:
patent: 7388089 (2008-06-01), Valenzuela et al.
Bowie et al (Science, 1990, 257:1306-1310).
Houghten et al. (Vaccines, 1986, Edited by Fred Brown: Cold Spring Harbor Laboratory).
Holmes, Exp. Opin.Invest. Drugs, 2001, 10(3):511-519).
Greenspan et al (Nature Biotechnology, 1999, 7:936-937).
Adler and Theodor, “The mouthparts, alimentary tract and salivary apparatus of the femalePhlebotomus papatasi,” Ann. Trop. Med. Parasitol. 20:109, 1926.
Barral et al., “Human immune response to sand fly salivary gland antigens: a useful epidemiological marker?”Am. J. Trop. Med. Hyg. 62(6):740-745, 2000.
Belkaid et al., “A natural model ofLeishmania majorinfection reveals a prolonged ”silent“ phase of parasite amplification in the skin before the onset of lesion formation and immunity,”J. Immunol. 165:969-977, 2000.
Belkaid et al., “Delayed-type hypersensitivity toPhlebotomus papatasisand fly bite: an adaptive response induced by the fly?”Proc. Natl. Acad. Sci. USA97:6704-6709, 2000.
Belkaid et al., “Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome ofLeishmania majorinfection in the mouse ear dermis,”J. Exp. Med. 188:1941-1953, 1998.
Charlab et al., “Toward an understanding of the biochemical and pharmacological complexity of the saliva of a hematophagous sand flyLutzomyia longipalpis,” Proc. Natl. Acad. Sci. USA26:15155-15160, 1999.
Gurunathan et al., “Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected withLeishmania major,” J. Exp. Med. 186:1137-1147, 1997.
Gurunathan et al., “Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection,”Nat. Med. 4:1409-1415, 1998.
Kamhawi et al., “Protection against cutaneous leishmaniasis resulting from bites of uninfected sand flies,”Science290:1351-1354, 2000.
Katz et al., “Adenosine, AMP, and protein phosphatase activity in sand fly saliva,”Am. J. Trop. Med. Hyg. 62:145-150, 2000.
Lerner et al., “Isolation of maxadilan, a potent vasodilatory peptide from the salivary glands of the sand flyLutzomyia longipalpis,” J. Biol. Chem. 266:11234-11236, 1991.
M. Lamine Mbow,The Journal of Immunology, 161:5571-5577, 1998.
Méndez et al., “The potency and durability of DNA- and protein-based vaccines againstLeishmania majorevaluated using low dose, intradermal challenge,”J. Immunol. 166(8):5122-5128, 2001.
Modi and Tesh, “A simple technique for mass rearingLutzomyia longipalpisandPhlebotomus papatasi(Diptera: Psychodidae) in the laboratory,”J. Med. Ent. 20:568-569, 1983.
Qureshi et al., “Immunomodulatory properties of maxadilan, the vasodilator peptide from sand fly salivary gland extracts,”Am. J. Trop. Med. Hyg. 54:665-671, 1996.
Ribeiro et al., “Blood-finding strategy of a capillary-feeding sand fly,Lutzomyia longipalpis,” Comp. Biochem. Physiol. 83A:683-686, 1986.
Ribeiro et al., “Salivary apyrase activity of some Old World phlebotomine sand flies,”Insect Biochem. 19:409-412, 1989.
Ribeiro et al., “Salivary glands of the sand flyPhlebotomus papatasicontain pharmacologically active amounts of adenosine and 5′-AMP,”J. Exp. Biol. 202:1551-1559, 1999.
Sjölander et al., “Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis,”J. Immunol. 160:3949-3957, 1998.
Smelt et al., “B cell-deficient mice are highly resistant toLeishmania donovaniinfection, but develop neutrophil-mediated tissue pathology,”J. Immunol. 164:3681-3688, 2000.
Theodos et al., “Analysis of enhancing effect of sand fly saliva onLeishmaniainfection in mice,”Infect. Immun. 59:1592-1598, 1991.
Titus et al., “Salivary gland lysates from the sand flyLutzomyia longipalpisenhancedLeishmania infectivity,” Science239:1306-1308, 1988.
Valenzuela et al., “The salivary apyrase of the blood-sucking sand flyPhlebotomus papatasibelongs to the novelCimexfamily of apyrases,”J. Exp. Biol. 204:229-237, 2001.
Valenzuela et al., “Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein,”The Journal of Experimental Medicine, 194(3):331-342, 2001.
Volf et al., “Salivary proteins and glycoproteins in phlebotomine sandflies of various species, sex and age,”Medical and Veterinary Entomology, 14(3):251-256, 2000.
Volf and Rohousova, “Species-specific antigens in salivary glands of phlebotomine sandflies,”Parasitology, 122(1):37-41, 2001.
Waitumbi et al.,Infect. Immun., 66(4): 1534-1537, Apr. 1998.
Xu and Liew, “Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, ofL. major,” Immunology84:173-176, 1995.
Belkaid Yasmine
Kamhawi Shaden
Ribeiro José M. C.
Sacks David
Valenzuela Jesus G.
Baskar Padma V
Duffy Patricia A
Klarquist Sparkman LLP.
The United States of America as represented by the Secretary of
LandOfFree
Anti-arthropod vector vaccines, methods of selecting and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-arthropod vector vaccines, methods of selecting and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-arthropod vector vaccines, methods of selecting and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2654777